Qingdao Baheal Medical INC.
百洋医药
301015
Shenzhen Stock Exchange
Company Overview
Qingdao Baheal Medical Inc. (Baheal Medical), listed on the ChiNext board of the Shenzhen Stock Exchange under stock code 301015, was founded in 2005. The company operates as an innovation brands commercialization platform, focusing on the development, manufacturing, and commercialization of medical innovations. Baheal Medical aims to optimize medical practices through technological advancements. The company specializes in modern traditional Chinese medicine (TCM) and advanced controlled-release formulations, supported by a robust R&D and production system for both TCM and chemical medicines. Baheal Medical has launched numerous innovative products with proprietary intellectual property rights and has a strong emphasis on technological development. It has built a comprehensive nationwide sales and marketing network, facilitating the adoption of high-quality medical products in clinical settings. The company has developed a diverse product portfolio that includes Over the Counter (OTC) and prescription medicines, oncology drugs, and high-end medical devices, addressing various healthcare needs across society.
AI-generated from company disclosures and CNInfo data.
Company Profile
Through our core technical capabilities in modern traditional Chinese medicine (TCM) and advanced controlled-release formulations, Baheal Medical has established a sophisticated R&D and production system for both TCM and chemical medicines. We have successfully launched a variety of innovative products with proprietary intellectual property rights, and consistently drive forward technological development and production for upstream medical innovations. Leveraging our well-established commercialization capabilities and extensive nationwide sales and marketing network, Baheal Medical accelerates the adoption of high-quality medical and health products in clinical practices. It has incubated multiple leading brands in the field of bone health, liver disease and metabolic disorders, and has established a rich product matrix covering Over the Counter (OTC) and general health, OTX and prescription medicine, oncology drugs, as well as high-end medical devices to meet the various healthcare needs of the entire society.
Key Financials
As of 2026-08-01T00:00:00.000+00:00Announcements
Notes & Comments
Sign in to leave a comment or private note.
No notes or comments yet.